The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over

Inclusion Criteria: * Male and female patients aged ≥ 55 years suffering from non-organic insomnia according to International Classification of Diseases (ICD-10) * Patients with sleep disorders manifested as poor sleep quality associated with impaired daytime functioning with or without one or more of the following criteria: difficulty falling asleep, frequent night awakenings, early morning awakenings * Patients able to follow the study protocol * Patients who have signed the Informed Consent prior to initiation of any observation-related procedures * Patients with a global score of ≤17 inclusively on the modified Questionnaire Scoring Subjective Characteristics of Sleep * Patients who have just been identified to receive treatment with Circadin * Patients without previous treatment with Circadin Exclusion Criteria: * Hypersensitivity to any components of Circadin * Congenital galactose intolerance, glucose-galactose malabsorption, Lapp lactase deficiency * Pregnancy and lactation * Alcohol or drug addiction * Severe somatic and neurological conditions, exacerbations thereof, including autoimmune diseases or renal/hepatic insufficiency * Intake of psychoactive medicines within the last 30 days before observational study entry * Presence of clinically significant anxiety and depression as assessed by the Hospital Anxiety and Depression Scale * Presence of pain that might be the cause for insomnia. Subjects suffering from breathing related sleep disorders